Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $62.8333.

SUPN has been the topic of a number of research analyst reports. Weiss Ratings restated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Zacks Research raised Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 6th. Cantor Fitzgerald increased their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an "overweight" rating in a research report on Thursday, July 9th. Finally, Wall Street Zen lowered Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, August 8th.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several large investors have recently made changes to their positions in SUPN. Public Employees Retirement System of Ohio purchased a new position in shares of Supernus Pharmaceuticals in the 2nd quarter worth about $25,000. Rockefeller Capital Management L.P. increased its holdings in Supernus Pharmaceuticals by 354.8% during the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company's stock worth $42,000 after buying an additional 660 shares during the last quarter. Torren Management LLC bought a new stake in Supernus Pharmaceuticals in the fourth quarter worth about $49,000. Hantz Financial Services Inc. raised its position in Supernus Pharmaceuticals by 73.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company's stock worth $54,000 after acquiring an additional 458 shares during the period. Finally, Global Retirement Partners LLC purchased a new position in Supernus Pharmaceuticals in the second quarter valued at about $64,000.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $45.85 on Monday. The firm has a 50-day moving average of $46.74 and a 200-day moving average of $48.83. Supernus Pharmaceuticals has a one year low of $42.45 and a one year high of $59.68. The company has a market cap of $2.67 billion, a P/E ratio of -23.88, a P/E/G ratio of 0.85 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The firm had revenue of $219.06 million for the quarter, compared to analysts' expectations of $205.31 million. During the same quarter last year, the firm posted $0.40 earnings per share. The firm's revenue for the quarter was up 32.4% compared to the same quarter last year. As a group, research analysts expect that Supernus Pharmaceuticals will post 1.97 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source